Karolinska University Hospital — Sponsor Intelligence | 58 EU Trials

Filter these 58 trials by condition, phase, country and more.

Open in Search →

58 Registered trials

31 Recruiting

13 Completed trials

18 Countries active

105 Unique IMPs

100% Results reported

Phase III

Phase II

Phase IV

Phase I (Other)

Phase III: 12 Phase II/III: 2 Phase II: 26 Phase I/II: 2 Phase III/IV: 2 Phase IV: 6 Phase I: 1 Phase I (Other): 6 Other: 1

Oversight events:

3 serious breaches 6 temporary halts across 2 trials

View oversight register →

100%

13 of 13 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer 2 Follicular lymphoma 1 Malignant melanoma stage III 1 Ovarian cancer 1 Rheumatoid arthritis 1 Thyroid cancer stage IV 1 Anaplastic thyroid cancer 1 Breast cancer stage II 1 Eastern Cooperative Oncology Group performance status 1 Hyperthyroidism 1 Prostate cancer recurrent 1 Squamous cell carcinoma of the vulva 1

Top IMPs

PACLITAXEL 3 PREDNISOLONE 3 CARBOPLATIN 2 CYTARABINE 2 DEXAMETHASONE 2 DOCETAXEL 2 GALLIUM (68GA) TEZATABEP MATRAXETAN 2 LETROZOLE 2 METHOTREXATE 2 NIVOLUMAB 2 PERTUZUMAB 2 SEMAGLUTIDE 2

All trials — page 3

58 total

A randomized double blind, multicenter trial to assess time-interval between cytoreductive surgery and adjuvant chemotherapy after administr… Ended

2023-507732-20-00 Phase III 1 country
HEAT-AML (Hydroxyurea-Enhanced Ara-C Treatment of Adult Acute Myeloid Leukaemia): A clinical study to assess whether addition of hydroxyurea… Ended

2023-509019-97-00 Phase I/II 1 country CYTARABINE; DAUNORUBICIN; HYDROXYCARBAMIDE
PREDIX Luminal B - Neoadjuvant response-guided treatment of estrogen receptor positive tumors with high proliferation or slow proliferation … Ended

2024-519019-32-00 Phase II 1 country ANASTROZOLE; EXEMESTANE; LETROZOLE; PACLITAXEL; PALBOCICLIB; TAMOXIFEN
PREDIX HER2 - preoperative treatment of HER2 positive breast cancer Ended

2023-508411-23-00 Phase II 1 country DOCETAXEL; PERTUZUMAB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE
Investigator initiated clinical trial of dantrolene as a treatment for Darier disease Ended

2024-519201-36-00 Phase II 1 country DANTROLENE SODIUM
BIOMarkers in Endometrial Cancer - A phase III open label randomized trial to determine the efficacy of biomarker staging as compared to con… Ended

2023-505991-31-00 Phase III 1 country
Molecular PD-L1 PET/CT Imaging with 89Zr-atezolizumab to Monitor Immune Responses in metastatic Triple Negative Breast Cancer Ended

2022-500808-21-00 Phase II 1 country ATEZOLIZUMAB; PACLITAXEL ALBUMIN-BOUND
Octreotide treatment to improve nutritional recovery after surgery for patients with esophageal or gastric cancer, a prospective randomized … Ended

2022-502745-98-00 Phase II 1 country OCTREOTIDE
Intermittent ibrutinib in chronic lymphocytic leukemia Ended

2023-508638-32-00 Phase I (Other) 2 countries
ME-401 combined with rituximab-bendamustine for high-risk and rituximab with a 1:1 randomization to ME-401 for low-risk follicular lymphoma … Ended

2022-501138-49-00 Phase II 1 country

Showing 49–58 of 58 trials

← All sponsors A–Z